{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:10:20Z","timestamp":1774930220269,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019311","name":"Northwell Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.eprac.2023.11.014","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T03:02:25Z","timestamp":1702177345000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia"],"prefix":"10.1016","volume":"30","author":[{"given":"Benjamin","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael Tobi","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4604-0879","authenticated-orcid":false,"given":"Rifka","family":"Schulman-Rosenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2023.11.014_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.014_bib3","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.014_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2337\/diacare.21.2.246","article-title":"Unrecognized diabetes among hospitalized patients","volume":"21","author":"Levetan","year":"1998","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2023.11.014_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2023.11.014_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2023.11.014_bib7","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.eprac.2023.11.014_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2023.11.014_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.014_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2023.11.014_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2023.11.014_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2023.11.014_bib13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2023.11.014_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.014_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1091","article-title":"Characteristics of and mortality associated with diabetic ketoacidosis among US patients hospitalized with or without COVID-19","volume":"4","author":"Pasquel","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.014_bib16","article-title":"Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors: a focused review of pathophysiology, risk factors, and triggers","volume":"13","author":"Somagutta","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.eprac.2023.11.014_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7074868","article-title":"Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis","volume":"2018","author":"Yu","year":"2018","journal-title":"Int J Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2023.11.014_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"issue":"7","key":"10.1016\/j.eprac.2023.11.014_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2023.11.014_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107797","article-title":"Defining and characterising diabetic ketoacidosis in adults","volume":"155","author":"Dhatariya","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.014_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcjd.2021.04.006","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis","volume":"46","author":"Colacci","year":"2022","journal-title":"Can J Diabetes"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.014_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000284","article-title":"Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis","volume":"12","author":"Deshpande","year":"2023","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.014_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.eprac.2023.11.014_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/jcpt.13107","article-title":"The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?","volume":"45","author":"Koufakis","year":"2020","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.014_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"issue":"7","key":"10.1016\/j.eprac.2023.11.014_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11892-017-0874-3","article-title":"SGLT2-I in the hospital setting: diabetic ketoacidosis and other benefits and concerns","volume":"17","author":"Levine","year":"2017","journal-title":"Curr Diab Rep"},{"issue":"9","key":"10.1016\/j.eprac.2023.11.014_bib28","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence","volume":"28","author":"Mehta","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.014_bib29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.jvca.2023.01.041","article-title":"Postcardiac surgery euglycemic diabetic ketoacidosis in patients on sodium-glucose cotransporter 2 inhibitors","volume":"37","author":"Auerbach","year":"2023","journal-title":"J\u00a0Cardiothorac Vasc Anesth"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.014_bib30","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2023.11.014_bib31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00592-023-02138-4","article-title":"Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial)","volume":"60","author":"Kuchay","year":"2023","journal-title":"Acta Diabetol"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.014_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diabet.2020.01.002","article-title":"Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.014_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"issue":"7","key":"10.1016\/j.eprac.2023.11.014_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/11630900-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of linagliptin","volume":"51","author":"Graefe-Mody","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.eprac.2023.11.014_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.108052","article-title":"The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors","volume":"35","author":"Huang","year":"2021","journal-title":"J\u00a0Diabetes Complications"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.014_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101285","article-title":"The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection","volume":"47","author":"Delanaye","year":"2021","journal-title":"Diabetes Metab"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2023.11.014_bib37","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/cc968","article-title":"Pathophysiology of fluid imbalance","volume":"4","author":"Kreimeier","year":"2000","journal-title":"Crit Care"},{"key":"10.1016\/j.eprac.2023.11.014_bib38","series-title":"Textbook of Emergency General Surgery: Traumatic and Non-traumatic Surgical Emergencies","first-page":"137","article-title":"Hypovolemic shock","author":"Jones","year":"2023"},{"key":"10.1016\/j.eprac.2023.11.014_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.973129","article-title":"Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: a meta-analysis of randomized controlled trials","volume":"9","author":"Rong","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.014_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PTS.0000000000000163","article-title":"Medications and patient characteristics associated with falling in the hospital","volume":"14","author":"O\u02bcNeil","year":"2018","journal-title":"J\u00a0Patient Saf"},{"issue":"7","key":"10.1016\/j.eprac.2023.11.014_bib41","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC201710030","article-title":"Urinary tract infection","volume":"167","author":"Gupta","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.014_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ajic.2003.08.007","article-title":"Inappropriate use of urinary catheters in elderly patients at a midwestern community teaching hospital","volume":"32","author":"Gokula","year":"2004","journal-title":"Am J Infect Control"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.014_bib44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1060028020951928","article-title":"Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors","volume":"55","author":"Engelhardt","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eprac.2023.11.014_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol Res"},{"issue":"13","key":"10.1016\/j.eprac.2023.11.014_bib46","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s11606-023-08161-z","article-title":"National norms for hospitalizations due to ambulatory care sensitive conditions among Adults in the US","volume":"38","author":"Loyd","year":"2023","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.014_bib47","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.014_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7748\/ns.2022.e11959","article-title":"Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes","volume":"38","author":"Noble-Bell","year":"2023","journal-title":"Nurs Stand"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:16:20Z","timestamp":1712034980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23007772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1530891X23007772"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.11.014","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}